Patients' preferences for osteoporosis drug treatment: A discrete choice experiment

Osteoporosis International

Volumn 19, Issue 7, 2008, Pages 1029-1037

  De Bekker Grob, E W ^a   Essink Bot, M L ^a   Meerding, W J ^a   Pols, H A P ^a   Koes, B W ^a   Steyerberg, E W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Discrete choice experiment; Drug treatment; Osteoporosis; Preferences; Prevention

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFICACY; FEMALE; GENERAL PRACTICE; HEALTH CARE COST; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NAUSEA; NETHERLANDS; OSTEOPOROSIS; PATIENT ATTITUDE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUESTIONNAIRES; RISK FACTORS;

EID: 44649097129     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0535-5     Document Type: Article

References (31)

1. Riggs BL, Melton LJ 3rd (1995) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(5 Suppl):505S-511S
2. Silverman SL (2005) Quality-of-life issues in osteoporosis. Curr Rheumatol Rep 7(1):39-45
3. Atik OS, Gunal I, Korkusuz F (2006) Burden of osteoporosis. Clin Orthop Relat Res 443:19-24
4. Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, Thompson DE, Karpf DB (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157(22):2617-2624
5. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9(5):461-468
6. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535-1541
7. Meunier PJ (1999) Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials. Int J Clin Pract 53(2):122-129
8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344-1352
9. Guideline on osteoporosis. Utrecht: The Dutch Institute for Healthcare Improvement (CBO); 2002
10. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D (1997) Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 7(4):390-406
11. Gyrd-Hansen D, Sogaard J (2001) Analysing public preferences for cancer screening programmes. Health Econ 10(7):617-634
12. Ryan M, Hughes J (1997) Using conjoint analysis to assess women's preferences for miscarriage management. Health Econ 6(3):261-273
13. Ryan M, Farrar S (2000) Using conjoint analysis to elicit preferences for health care. BMJ 320(7248):1530-1533
14. Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M (2004) Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ 328(7436):382
15. Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M (2004) Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 172(6 Pt 1):2321-2325
16. Aristides M, Weston AR, FitzGerald P, Le Reun C, Maniadakis N (2004) Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment. Value Health 7(4):442-454
17. Weston A, Fitzgerald P (2004) Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma. Pharmacoeconomics 22(18):1195-1208
18. Lee A, Gin T, Lau AS, Ng FF (2005) A comparison of patients' and health care professionals' preferences for symptoms during immediate postoperative recovery and the management of postoperative nausea and vomiting. Anesth Analg 100(1):87-93
19. Bishai D, Brice R, Girod I, Saleh A, Ehreth J (2007) Conjoint analysis of French and German parents' willingness to pay for meningococcal vaccine. Pharmacoeconomics 25(2):143-154
20. Farrar S, Ryan M, Ross D, Ludbrook A (2000) Using discrete choice modelling in priority setting: an application to clinical service developments. Soc Sci Med 50(1):63-75
21. Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM, Napper M, Robb CM (2001) Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 5(5):1-186
22. Louviere JJ, Hensher DA, Swait JD (2000) Stated choice methods: analysis and application. Cambridge University Press, Cambridge
23. Hahn GJ, Shapiro SS (1966) A catalog and computer program for the design and analysis of orthogonal symmetric and asymmetric fractional factorial experiments. General Electric Research and Development Center, Schenectady, NY, USA
24. Lloyd A, McIntosh E, Price M (2005) The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment. Pharmacoeconomics 23(11):1167-1181
25. Mahadevia P, Shah S, Mannix S, Brewster-Jordan J, Kleinman L, Liebman C, O'Dowd L (2006) Willingness to pay for sensory attributes of intranasal corticosteroids among patients with allergic rhinitis. J Manag Care Pharm 12(2):143-151
26. Lancsar EJ, Hall JP, King M, Kenny P, Louviere JJ, Fiebig DG, Hossain I, Thien FC, Reddel HK, Jenkins CR (2007) Using discrete choice experiments to investigate subject preferences for preventive asthma medication. Respirology 12(1):127-136
27. Fraenkel L, Constantinescu F, Oberto-Medina M, Wittink DR (2005) Women's preferences for prevention of bone loss. J Rheumatol 32(6):1086-1092
28. Fraenkel L, Gulanski B, Wittink D (2006) Patient treatment preferences for osteoporosis. Arthritis Rheum 55(5):729-735
29. Bartl R, Gotte S, Hadji P, Hammerschmidt T (2006) [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment] Adharenz mit taglichen und wochentlichen oralen Bisphosphonaten in der Osteoporosetherapie. Dtsch Med Wochenschr 131(22):1257-1262
30. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15(12):1003-1008
31. Blotman F, Cortet B, Hilliquin P, Avouac B, Allaert FA, Pouchain D, Gaudin AF, Cotte FE, El Hasnaoui A (2007) Characterisation of patients with postmenopausal osteoporosis in French primary healthcare. Drugs Aging 24(7):603-614